Realizing the promise.
We are at the cusp of a revolution in medicine. Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.
Aoife Brennan, MB, BCh, BAO, MRCPI
Aoife Brennan, MB, BCh, BAO, MRCPI
Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018. She joined Synlogic in September 2016 as chief medical officer. Prior to Synlogic, Aoife spent six years at Biogen, most recently as vice president and head of the Rare Disease Innovation Unit, developing programs from pre-clinical to commercial. She has led programs across multiple therapeutic areas including the successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A, respectively.
Aoife serves as a member of the Board of Directors of Cerevance and Fibrogen, Inc, and previously served on the Board of Directors of Ra Pharmaceuticals until it’s acquisition by UCB. Earlier in her career, Aoife led clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes.
Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
JAMIE AUSTIN, PHD, RAC
Jamie Austin, PHD, RAC
Jamie’s regulatory expertise spans small molecule pharmaceuticals, biologics/biosimilars, advanced therapies, medical devices, and combination products in various therapeutic areas. She has worked on navigating the regulatory framework over six novel cell and gene therapy programs as well as four unique biosimilar products in the US and abroad. Over the course of her career, Dr. Austin has also executed regulatory strategies in support of approvals for VIEKIRA/HOLKIRA PAK, TAGRISSO, and FASLODEX, as well as numerous medical devices.
Dr. Austin earned her B.S. in Chemical Engineering from the University of Notre Dame and M.S. in Bioscience Regulatory Affairs from the Johns Hopkins University. She received her Ph.D. in Pharmaceutical Sciences from the University of Michigan, where she studied the biological aspects of the Human Immunodeficiency Virus (HIV). Dr. Austin is Regulatory Affairs Certified by the Regulatory Affairs Professional Society in both US and Canadian regulatory affairs.
Antoine Awad
Antoine Awad
Gregg Beloff
Gregg Beloff
Michael Conlon
Michael Conlon
Mike started out his career at Pfizer where he worked in the discovery drug metabolism group and was part of the original discovery team that developed Chantix. Mike holds a BA in biochemistry from Skidmore College and an MBA from the Tuck School of Business at Dartmouth.
Molly Harper
Molly Harper
Ms. Harper is an experienced biotech leader with a demonstrated track record of translating development assets into commercialized products. Ms. Harper joins Synlogic from Relmada Therapeutics, Inc. where she served as Executive Vice President of Operations. Prior to Relmada she served in positions of increasing responsibility with Akcea Therapeutics, including most recently as Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the commercialization of two rare disease drugs. Ms. Harper was also Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme, having previously served at various positions in sales and marketing with Merck & Co, and equity research at UBS Warburg.
DAVID HAVA, PHD
David Hava, PhD
Caroline B. Kurtz, PhD
Caroline B. Kurtz, PhD
Daniel Rosan
Daniel Rosan
Dan brings broad expertise in strategy, long range planning, valuation, corporate development, capital allocation, and portfolio management. He previously spent six years at Biogen in roles of increasing responsibility in Finance and Research & Development and supported significant corporate transactions. Most recently he directed Biogen’s R&D Resource & Performance Management team, which provided project management for assets from pre-clinical through clinical proof of concept; drove the integration of external assets and companies into Biogen’s R&D organization; and led R&D business & portfolio planning.
Earlier in his career, Dan was a management consultant with Frankel Group (acquired by Huron Life Sciences in 2014), a boutique firm serving biotechnology companies and investors. He began his career as a public health advocate and community organizer. Dan holds a BA in History from Vassar College and an MBA from Harvard Business School.
Brendan St. Amant
Brendan St. Amant
